Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Thiazolidinedione monotherapy for T2DM tied to lower dementia risk
Oct 12, 2022
Sulfonylurea monotherapy was linked to increased risk for all-cause dementia compared with metformin monotherapy.
Newly diagnosed diabetes at COVID-19 admission profiled
Mar 02, 2022
Lower levels of glucose and HbA1c, and higher levels of inflammatory markers, were seen in COVID-19 patients with newly diagnosed diabetes mellitus versus preexisting diabetes.
Monoclonal antibody therapy may cut COVID-19 hospitalizations
Aug 31, 2021
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.
Catheter ablation for atrial fibrillation cuts risk for dementia, death
Aug 25, 2023
The findings persisted across age, sex and comorbidities.
Modifiable risk factors tied to young-onset dementia
Dec 28, 2023
Some of the factors include social isolation, diabetes, heart disease, vitamin D deficiency, high C-reactive protein and low handgrip strength.
SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients
Dec 07, 2022
SGLT-2is are associated with the lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists and metformin.
Long-term glycemic control cuts risk for severe COVID-19 with type 2 diabetes mellitus
Dec 07, 2021
Additionally, the use of corticosteroids or a combo of metformin and insulin significantly cut intensive care risk.
Pioglitazone use linked to reduced dementia risk in T2DM
Feb 16, 2023
The reduction in risk was greatest for those with a history of ischemic heart disease or stroke.